Ensign Peak Advisors Inc Has $49.42 Million Holdings in CVS Health Co. (NYSE:CVS)

Ensign Peak Advisors Inc trimmed its position in CVS Health Co. (NYSE:CVS) by 19.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 836,747 shares of the pharmacy operator’s stock after selling 201,264 shares during the period. Ensign Peak Advisors Inc owned approximately 0.07% of CVS Health worth $49,418,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gryphon Financial Partners LLC grew its position in CVS Health by 48.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 8,151 shares of the pharmacy operator’s stock valued at $654,000 after purchasing an additional 2,653 shares in the last quarter. TCW Group Inc. acquired a new position in CVS Health during the fourth quarter valued at approximately $1,605,000. Team Hewins LLC acquired a new position in shares of CVS Health during the 4th quarter worth approximately $419,000. Congress Wealth Management LLC DE boosted its holdings in shares of CVS Health by 126.0% in the 4th quarter. Congress Wealth Management LLC DE now owns 6,827 shares of the pharmacy operator’s stock valued at $539,000 after buying an additional 3,806 shares during the last quarter. Finally, Skopos Labs Inc. acquired a new position in CVS Health during the fourth quarter worth $533,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Performance

NYSE:CVS opened at $57.51 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.66 and a current ratio of 0.86. CVS Health Co. has a fifty-two week low of $52.77 and a fifty-two week high of $83.25. The company has a market cap of $72.20 billion, a price-to-earnings ratio of 10.11, a PEG ratio of 0.79 and a beta of 0.53. The stock has a fifty day moving average price of $58.31 and a 200-day moving average price of $62.52.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.73 by $0.10. The firm had revenue of $91.23 billion for the quarter, compared to the consensus estimate of $91.41 billion. CVS Health had a net margin of 1.98% and a return on equity of 12.72%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.21 earnings per share. As a group, equities analysts anticipate that CVS Health Co. will post 6.51 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Monday, October 21st will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.63%. The ex-dividend date is Monday, October 21st. CVS Health’s payout ratio is presently 46.75%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CVS shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $62.00 price objective on shares of CVS Health in a research report on Monday, September 16th. Wells Fargo & Company upped their price objective on CVS Health from $60.00 to $61.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Barclays reduced their target price on CVS Health from $65.00 to $63.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $68.00 price target on shares of CVS Health in a report on Wednesday, September 4th. Finally, Robert W. Baird started coverage on shares of CVS Health in a report on Thursday, May 30th. They issued a “neutral” rating and a $61.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $72.10.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.